Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...

PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Advancing rare disease care with innovation, trials, and specialised clinics ...

The Human Genome Project, launched in 1990 and completed in 2003, also moved the needle. Scientists had successfully ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Many born with the genetic disorder thalassaemia major die before the age of 10. Donated blood can help keep them alive.

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

With the bull market starting its fourth year, and yields on U.S. debt falling to the lowest levels since early this year, ...

India faces a silent anaemia epidemic, with rising cases across all demographics. In most cases, public tend to disregard its ...